Free Trial
NASDAQ:UNCY

Unicycive Therapeutics 8/14/2025 Earnings Report

Unicycive Therapeutics logo
$7.06 -1.02 (-12.62%)
As of 05/26/2026 04:00 PM Eastern

Unicycive Therapeutics EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.70
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A

Unicycive Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unicycive Therapeutics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Unicycive Therapeutics' next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules.

Conference Call Resources

Unicycive Therapeutics Earnings Headlines

ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Unicycive Therapeutics Inc Ordinary Shares UNCY
See More Unicycive Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email.

About Unicycive Therapeutics

Unicycive Therapeutics (NASDAQ:UNCY), a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

View Unicycive Therapeutics Profile